Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials
HORIZON JU Research and Innovation Actions
Basic Information
- Identifier
- HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage
- Programme
- Research and Innovation actions supporting the Global Health EDCTP3 Joint Undertaking
- Programme Period
- 2021 - 2027
- Status
- Closed (31094503)
- Opening Date
- January 18, 2024
- Deadline
- April 4, 2024
- Deadline Model
- two-stage
- Budget
- €24,000,000
- Min Grant Amount
- €6,000,000
- Max Grant Amount
- €6,000,000
- Expected Number of Grants
- 4
- Keywords
- HORIZON-JU-GH-EDCTP3-2024-01-04-two-stageHORIZON-JU-GH-EDCTP3-2024-01-two-stageAntimicrobial resistanceAntimicrobialsClinical researchClinical trialsGlobal healthInfectious diseasesPrevention and treatment of infection by pathogens (e.g. vaccination, antibiotics, fungicide)Public health
Description
Activities funded under the 2024 work programme of the Global Health EDCTP3 JU calls for proposals should contribute to:
- reduce the individual, social, and economic burdens of infectious diseases in sub-Saharan Africa through the development and uptake of new or improved interventions, and
- increase health security in sub-Saharan Africa and globally by reducing the risk of outbreaks and pandemics and enhancing national and regional capacity to address antimicrobial resistance.
- Progressing towards the achievement of SDG3 ‘Ensure healthy lives and promote well-being for all at all ages’ in sub-Saharan African (SSA) countries;
- Enable the implementation of the short- and medium-term actions foreseen by the AU EU Innovation Agenda (adopted in July 2023) in the area of public health and the EU Global Health Strategy (November 2022);
- Improve equitable access to a full range of essential health services from health promotion to disease prevention and affordable quality treatment, rehabilitation and palliative care to fight communicable diseases;
- Expand partnerships based on equal footing, co-ownership, mutual interest and strategic priorities;
- Provide evidence for informed health policies and guidelines within public health systems in SSA and at international level;
- Enhance sustainable global scientific collaboration in health research and international cooperation across SSA;
- Develop novel, innovative HIV therapeutics for reducing the disease burden of HIV in SSA
- Research on existing Malaria vaccines and development of new promising candidates
- Accelerating development and integration of therapeutics against neglected tropical diseases (NTDs) in SSA;
- Tackle Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials
- Develop new tools, technologies and approaches for vector control in SSA;
- Develop innovative digital health solutions for SSA.
- Build appropriate local capacity.
Proposals under this topic should aim to deliver results that are directed, tailored towards, and contributing to the following expected outcomes. Proposals need to address at least two of these, with the first bullet point being compulsory:
- Improvement of the use of existing antimicrobials to reduce AMR and providing data contributing to their equitable access in sub-Saharan Africa, and/or the advancement of late-stage clinical R&D of novel antimicrobials with improved properties (efficacy, safety, resistance pattern, useability) in the clinical trials pipeline;
- Data about development and implementation of antimicrobial stewardship (AMS) processes to optimise the use of antimicrobial medicines in human health and reduce antimicrobial resistance (AMR), employing the One Health approach;
- Effective infection prevention control measures, sanitation and hygiene to reduce the need for and the use of antimicrobial medicines.
Background:
The WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Each year, at least 1.27 million people die as a consequence of AMR, with Africa having the world’s highest mortality rate from AMR infections, resulting in over 27 deaths per 100,000[1]. Without action, the death toll could rise even higher, to as many as 10 million deaths annually by 2050.[2]
Tackling AMR requires multi-modal interventions, the collaboration of many disciplines and countries. According to the Organisation for Economic Co-operation and Development (OECD), measures to prevent infections such as vaccinations, promoting hand hygiene and better hygiene in health-care facilities more than halves the risk of death and decreases the health burden of AMR. Antimicrobial stewardship (AMS) could further reduce the burden of drug-resistant infection[3]. The WHO defines AMS as a coherent set of integrated actions which promote the responsible and appropriate use of antimicrobials to help improve patient outcomes across the continuum of care. Responsible and appropriate use of antimicrobials includes prescribing only when needed, selection of the optimal drug regime, drug dosing, route of administration and duration of treatment following proper and optimized diagnosis. These actions are complemented by the implementation of infection prevention and control (IPC), enhancing water, sanitation and hygiene (WASH), and optimizing vaccination coverage.[4]
AMR is one of the Global Health issues which can hugely benefit from the employment of the One Health approach. The One Health approach is defined as a joint effort of various disciplines that come together to provide solutions for human, animal, and environmental health, including food safety[5]; more information can also be found in the Global research priorities agenda for One Health AMR[6]. AMR transmission is a critical global problem affecting humans, the environment, and animals. Hence, proposals need to have the One Health approach at their centre.[7]
Furthermore, the availability and access to existing antibiotics is also a challenge[8]. The Global Leaders Group on AMR recently established that the world faces a serious antibiotic pipeline and access crisis that requires innovative financing measures. In particular, efforts to ensure equitable access to antibiotics in LMICs that experience the highest burden of AMR, are needed.
Scope:
Proposals must address at least two of the following areas, with the delivery of the first bullet point being compulsory:
- Conduct R&D on the better use of existing antimicrobials to reduce AMR and provide data to contribute to their equitable access in SSA, and/or conduct late-stage clinical R&D on novel antimicrobials with improved properties (efficacy, safety, resistance pattern, useability) for infections within the scope of EDCTP3 to reduce AMR;
- Develop innovative antimicrobial stewardship strategies in human health on how to tackle AMR based on the One Health approach within the scope of EDCTP3 in SSA;
- Develop and implement cost effective, acceptable and feasible infection prevention and control (IPC) strategies, in reducing AMR in healthcare facilities and communities.
Only proposals focusing their research on existing and/or novel antimicrobials from phase 3 onwards will be eligible. Neither pre-clinical research nor early-stage clinical trials in the context of product development are within the scope of this call.
The inclusion of industry partners involved in the development and/or manufacturing of the antimicrobials in the consortium is strongly encouraged.
Where possible, collaboration and coordination with the Team Europe Initiative on Sustainable Health Security in Africa or Manufacturing and health products (TEI-MAV+) is encouraged. The applicants could show, for example, willingness to enter into technology transfer agreements with African counterparts - including the provision of patents, technical knowledge and know-how -, or early engagement with regulators or with African manufacturers to support the translation into affordable products adapted to the regional market.
Environmental aspects relating to antimicrobial resistance in the production of antimicrobials and the waste of antimicrobials should be considered.
For the purposes of this call, existing antimicrobials are classified as those already on the market, but impacted by AMR, and in need of improvement of their use to minimise AMR, whilst by novel antimicrobials we refer to those in the clinical trial development pipeline, but not yet on the market.
Proposals should assess the impact, contribution, utility, accessibility, equity and cost-effectiveness of proposed interventions on AMR across socioeconomic settings in SSA.
Sepsis is included in the scope of this call. According to the Berlin Declaration on Sepsis, calling upon the enforcement of the WHA70.7 resolution, sepsis should be tackled as part of actions against AMR to maximise efficiencies and reduce the burden of disease.[9]
Applicants are encouraged to work among international sectors and actors, including human and veterinary medicine, agriculture, finance and environment experts.
Applicants need to concisely describe any proven research evidence of previous findings and explain how the proposal builds on these results.
Proposals should present a sound assessment of the feasibility of the proposed work, in particular as regard to the proposed clinical interventions. Realistic plans for recruitment of subjects (as part of the clinical trial plan with projected dates) should be presented and documented by demonstrated success from previous studies. The proposals should justify the choice of populations to be enrolled into the interventions. Relevant determining characteristics (such as socio-economic status) also need to be considered.
Proposals must assure that the clinical trials are conducted in line with national and international standards of research, to comply with current legislation, good clinical practice, ethics, and safety-related issues, as well as good manufacturing practice, as relevant.
Proposals should describe how stakeholder views of the proposal’s relevance and the study design have been incorporated into the work plan of the research proposal. Proposals should indicate explicitly the plans for good participatory practices for engaging stakeholders at every step of the research life cycle.
Proposals should provide details on the methodology for linking clinical research aspects with the translation into healthcare practice and policy.
For all proposed research activities, attention should be paid to critical social factors such as sex, gender, age, socio-economic factors, ethnicity/migration, and disability both in terms of the consortium composition and the selection of study participants. Vulnerable populations need to be included in the clinical study population, including children, pregnant women, people with co-infections and comorbidities, older people and people living in hard-to-reach communities (unless excluded for physiologic or metabolic reasons).
FAIR data principles and open access of publications are required.
All projects funded under this topic are strongly encouraged to participate in networking and joint activities, as appropriate.
Applicants are reminded of the expectation that proposals should come from research consortia with a strong representation of institutions and researchers from sub-Saharan African countries, including involvement of Franco/Lusophone countries if possible. Applicants are also reminded of the expectation of reaching out to organisations in countries with relatively lower research capacities.
[1] The Lancet AMR analysis: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext
[2] World Bank, Antimicrobial Resistance: https://www.worldbank.org/en/topic/health/brief/antimicrobial-resistance-amr and Global AMR R&D Hub and WHO, Incentivising the development of new antibacterial treatments 2023: https://globalamr.e-laborat.eu/incentivising-the-development-of-new-antibacterial-treatments-progress-report-by-the-global-amr-rd-hub-and-who/
[3] OECD, Stemming the Superbug Tide: https://www.oecd.org/els/stemming-the-superbug-tide-9789264307599-en.htm; Antimicrobial stewardship programmes in health-care facilities in low-and middle-income countries: a WHO practical toolkit: https://www.who.int/publications/i/item/9789241515481; A European One Health Action Plan against Antimicrobial Resistance (AMR): https://health.ec.europa.eu/antimicrobial-resistance/eu-action-antimicrobial-resistance_en#ref-2017-eu-one-health-action-plan-against-amr; Antimicrobial stewardship: can we add pharmacovigilance networks to the toolbox? https://link.springer.com/article/10.1007/s00228-020-03035-3
[4] WHO policy guidance on integrated antimicrobial stewardship activities: https://www.who.int/publications/i/item/9789240025530;
WHO Global research agenda for antimicrobial resistance in human health: https://www.who.int/publications/m/item/global-research-agenda-for-antimicrobial-resistance-in-human-health;
Global Action Plan on Antimicrobial resistance:
https://www.who.int/publications/i/item/9789241509763
[5] Antimicrobial resistance: global report on surveillance: https://iris.who.int/handle/10665/112642;
Council recommendation published in June 2023: https://www.consilium.europa.eu/en/press/press-releases/2023/06/13/tackling-antimicrobial-resistance-council-adopts-recommendation/#:~:text=Overall%2C%20the%20Council's%20recommendation%20seeks,become%20resistant%20to%20medical%20intervention
[6] WHO Global One Health priority research agenda for antimicrobial resistance: https://iris.who.int/bitstream/handle/10665/370279/9789240075924-eng.pdf?sequence=1
[7] ILRI One Health Strategy: Stopping the global rise of high-impact zoonotic disease, foodborne disease and antimicrobial resistance: https://cgspace.cgiar.org/bitstream/handle/10568/125264/OneHealthStrategy.pdf?sequence=1&isAllowed=y
[8] Progress report by the Global AMR R&D Hub and WHO 2023:
The Global Response to AMR, Wellcome Trust: https://wellcome.org/sites/default/files/wellcome-global-response-amr-report.pdf
[9] 2023 Berlin Declaration on Sepsis: https://www.esaic.org/esa-news/the-2030-world-sepsis-declaration/#:~:text=The%20Berlin%20Declaration%20on%20Sepsis%20is%20an%20urgent%20call%20for,reinvigorated%20global%20action%20on%20sepsis
Eligibility & Conditions
General conditions
2. Eligible countries: described in Annex B of the Work Programme General Annexes
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
Replacing relevant sections in General Annex B to the Horizon Europe work programmes on eligibility (“Entities eligible for funding”)
To become a beneficiary, legal entities must be eligible for funding.
To be eligible for funding, applicants must be established in one of the following countries:
- The Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden;
- The Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR);
- Countries associated to Horizon Europe [1]: Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo [2], Moldova, Montenegro, New Zealand (associated to Pillar II 'Global Challenges and European Industrial Competitiveness' as from the Work Programmes 2023 onwards, including for the institutionalised European partnerships), North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine, United Kingdom.
Until association agreements start producing legal effects either through provisional application or their entry into force, transitional arrangements apply. The transitional arrangements apply, at the time of the adoption of this Work Programme, with regard to the following countries and legal entities established in these countries, with which association negotiations are being processed or where association is imminent):
1. Canada
2. Morocco
- The following countries which are constituent states of the EDCTP Association [3]: Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Gabon, The Gambia, Ghana, Guinea-Bissau, Guinea-Conakry, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Republic of the Congo, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Tanzania, Uganda, Zambia, Zimbabwe.
Consortium composition
Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of the Global Health EDCTP3 JU, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes:
- At least three legal entities independent from each other and established in different countries, where legal entities are eligible to receive funding;
- At least one independent legal entity established in a Member State or an associated country; and
- At least one independent legal entity established in a sub-Saharan African (SSA) country that is a member of the EDCTP Association.
This condition applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
Specific cases:
Affiliated entities — Affiliated entities (i.e. entities with a legal or capital link to a beneficiary[4] which participate in the action with similar rights and obligations to the beneficiaries, but which do not sign the grant agreement and therefore do not become beneficiaries themselves) are allowed, if they are eligible for participation and funding.
Associated partners — Entities not eligible for funding (and therefore not able to participate as beneficiaries) may participate as associated partners, unless specified otherwise in the specific call conditions.
International organisations – International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.
Specific rules regarding legal entities that may be the coordinator of an indirect action
In accordance with Article 110(2) of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[5], where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the financial coordinator of the indirect action must be established in a Member State or associated country. Of the SSA countries members of the EDCTP Association, only South Africa concluded such an agreement at the moment.[6]
Scientific project leader
If the coordinator is not established in a country in sub-Saharan Africa (SSA), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity.
The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:
- During the call for proposals and selection process, coordinate meetings on and drafting of the full project proposal;
- Work with the coordinator and other beneficiaries on the drafting and negotiation of the consortium agreement and other legal agreements among the beneficiaries;
- Act as the key contact point for the Global Health EDCTP3 JU regarding all scientific action governance issues, steer and provide oversight in the development of the scientific actions, without prejudice to the tasks entrusted directly to the coordinator as per the Model Grant Agreement;
- Support and collaborate with the coordinator on its monitoring activities and the adoption of appropriate internal measures, to ensure that beneficiaries are fulfilling their obligations regarding budget, timeline, deliverables, and scientific quality;
- Review the action’s deliverables and reports before their submission by the coordinator;
- Lead the work packages(s) related to the tasks of scientific project leadership.
Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to the Global Health EDCTP3 JU on all issues of interest for the proper scientific management of the action.
[1] The list is correct at the time of adoption of this work programme. Please see the Horizon Europe List of Participating Countries on the Funding & Tenders Portal for up-to-date information on the current list and on the position for Associated Countries.
[2] This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.
[3] The list is correct at the time of adoption of this work programme. For an update, please check the EDCTP Association website www.edctp.org
[4] See Article 187 EU Financial Regulation 2018/1046.
[5] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014. OJ L 427, 30.11.2021, p. 17–119;
3. Other eligibility conditions: described in Annex B of the Work Programme General Annexes
4. Financial and operational capacity and exclusion: described in Annex C of the Work Programme General Annexes
-
Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes
Replacing the scores and weighting section in General Annex D to the Horizon Europe work programmes as regards Research and Innovation Actions (RIA) second stage of two-stage evaluations.
Scores and weighting
Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criteria 3 (Quality and efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.
Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.
Nota bene, for the first stage of the two-stage evaluation, the scores and weighting as indicated in Annex D of the General Annexes of the Horizon Europe work programme 2023/2024 apply. Furthermore, the scores and weighting for Coordination and Support Actions apply.
-
Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual
-
Indicative timeline for evaluation and grant agreement: described in Annex F of the Work Programme General Annexes
Also in line with Article 114 of the Council Regulation 2021/2085, participants will be subject to the following additional exploitation obligations:
- Participants must – up to four years after the end of the action (see Data Sheet, Point 1) – use their best efforts to ensure that resulting health technologies and services will be broadly available and accessible, as soon as possible and at fair and reasonable conditions. In this respect, if, despite a participants’ best efforts, the results are not exploited within one year after the end of the action, participants must (unless otherwise agreed in writing with the granting authority) use the Horizon Results Platform to find interested parties to exploit the results.
- In case the participants cannot fulfil the preceding obligation, the participants must (if requested by the granting authority) grant non-exclusive licences - under fair and reasonable conditions - to their results to legal entities that commit to rapidly and broadly exploiting the resulting health technologies and services and ensure that they are broadly available and accessible, as soon as possible and at fair and reasonable conditions.
- In case of transfer of the ownership or licensing of results, participants must pass on such additional exploitation obligations to the legal entities exploiting the results.
- For up to four years after the action (see Data Sheet, Point 1), the funding body must be informed every year about the status of the development of the product and any other exploitation of the results through an annual report that is due on each anniversary of the end of the grant agreement.
Implementing the provision on affordable access as defined in Article 114 of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[1], grants awarded under this topic will have to submit the following deliverables:
1. Stewardship plan
Participants must prepare stewardship plans outlining how to achieve the optimal use of an intervention, including, for example, how to avoid irrational use, overuse or abuse of health technologies (e.g. antimicrobials). A draft plan must be submitted after half the duration of the project has elapsed and a final plan must be submitted with the final report.
2. Global access plan
With the final report, participants must submit an appropriate and proportionate global access plan that covers registration targets, plans to meet demand, flexible approaches to IP and other strategies that reflect ability to pay and ensure that economic barriers to access are low.
[1] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014; OJ L 427, 30.11.2021, p. 17
6. Legal and financial set-up of the grants: described in Annex G of the Work Programme General Annexes
Specific conditions
7. Specific conditions: described in the [specific topic of the Work Programme]
Documents
Call documents:
Standard application form — call-specific application form is available in the Submission System
Standard application form (HE RIA, IA)
Standard application form (HE RIA IA Stage 1)
Standard evaluation form — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA)
Standard evaluation form (HE RIA, IA and CSA Stage 1)
MGA
Call-specific instructions
Additional documents:
GH EDCTP3 - WP 2024 Annex1A - Calls for Proposals
GH EDCTP3 - WP 2024 Annex1B - IKAA
HE Main Work Programme 2023–2024 – 1. General Introduction
HE Main Work Programme 2023–2024 – 4. Health
HE Main Work Programme 2023–2024 – 13. General Annexes
HE Framework Programme and Rules for Participation Regulation 2021/695
HE Specific Programme Decision 2021/764
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Support & Resources
Online Manual is your guide on the procedures from proposal submission to managing your grant.
Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.
Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.
The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search Services help you find a partner organisation for your proposal.
Latest Updates
EVALUATION RESULTS (Stage2)
Published: 17/01/2024
Deadline: 01/10/2024 (Stage2)
Available budget: EUR 136 432 000 (all topics)
The results of the evaluation for each topic are as follows:
HORIZON-JU-GH-EDCTP3-2024-01-01-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage | |
Number of proposals submitted (including proposals transferred from or to other calls) | 7 | 8 | 13 | 12 | 11 | 12 |
Number of inadmissible proposals | 0 | 0 | 0 | 0 | 0 | 0 |
Number of ineligible proposals | 0 | 0 | 0 | 0 | 0 | 0 |
Number of above-threshold proposals | 4 | 3 | 9 | 5 | 8 | 8 |
Total budget requested for above-threshold proposals | 23,412,255 | 35,321,242 | 47,572,585 | 27,808,182 | 48,569,614 | 41,757,842 |
Number of proposals retained for funding | 3 | 2 | 4 | 4 | 3 | 3 |
Number of proposals in the reserve list | 1 | 1 | 4 | 1 | 5 | 4 |
Funding threshold [1] | 14 | 13 | 14.5 | 13 | 13.5 | 14 |
Ranking Distribution | ||||||
Number of proposals with scores lower or equal to 15 and higher or equal to 14 | 3 | 1 | 5 | 0 | 2 | 3 |
Number of proposals with scores lower than 14 and higher or equal to 13 | 1 | 1 | 1 | 4 | 5 | 3 |
Number of proposals with scores lower than 13 and higher or equal to 10 | 0 | 1 | 3 | 1 | 1 | 2 |
[1] Proposals with the same score were ranked according to the priority order procedure set out in the call conditions (for HE, in the General Annexes to the Work Programme or specific arrangements in the specific call/topic conditions).
Summary of observer report:
"The evaluations were deemed, by the Independent Observers to be fair, impartial and equitable. No issues of confidentiality were seen to arise at any point. Additionally, no issues of non-conformity were observed to occur. The evaluations were found to have followed all the applicable rules. The eligibility of the proposals submitted was determined by the Global Health EDCTP3 team prior to experts being assigned to them. Any issues of proposals being / not being “in scope” were discussed by the experts during the consensus meetings.
The overall quality of the evaluations was judged to be very good by both observers. Importantly, no case was seen in which a proposal was evaluated such that it could be considered for funding despite not being of the necessary high quality."
We recently informed the applicants about the evaluation results for their proposals.
For questions, please contact [email protected]
The 2nd stage deadline has been postponed to 01/10/2024
EVALUATION RESULTS (STAGE 1)
Published: 17/01/24
Deadline: 04/04/24
Available budget: EUR 136 432 000
In accordance with the call conditions, the evaluation of the first-stage proposals was made looking only at the criteria 'Excellence' and 'Impact'. The threshold for both criteria was 4. The overall threshold (applying to the sum of the two individual scores) was set for each topic/type of action with separate call-budget-split at a level that allowed the total requested budget of proposals admitted to stage 2 be as close as possible to 3 times the available budget (and not below 2.5 times the budget):
- HORIZON-JU-GH-EDCTP3-2024-01-01-two-stage: 8 points
- HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage: 9 points
- HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage: 8 points
- HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage: 8 points
- HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage: 9.5 points
- HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage: 9.5 points
The results of the evaluation for each topic are as follows:
| HORIZON-JU-GH-EDCTP3-2024-01-01-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage | HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage | |
| Number of proposals submitted (including proposals transferred from or to other calls) | 14 | 21 | 20 | 26 | 49 | 70 |
| Number of inadmissible proposals | 0 | 0 | 0 | 0 | 0 | 1 |
| Number of ineligible proposals | 7 | 1 | 8 | 6 | 5 | 12 |
| Number of above-threshold proposals | 8 | 10 | 13 | 12 | 18 | 26 |
| Total budget requested for above-threshold proposals | 43.848.726 | 114.204.842 | 66.506.506 | 68.282.730 | 108.452.251 | 125.280.003 |
Summary of observer report:
The evaluations were in the estimation of both observers impartial, fair and equitable. No issues of confidentiality were seen to arise.
This was, in particular, enabled by a careful selection of experts and recorders as well as ensuring that any experts or recorders with a COI were excluded from the discussions of the proposal in question. The use of the SEP platform for all aspects of the reports (IER, CR and QC) also reinforced the confidentiality of the evaluation.
No issues of non-conformity were observed and the evaluation followed all the applicable rules. The eligibility of proposals was determined by the Unit prior to the assignment of experts to proposals. Any issues of proposals being not being “in scope” were discussed by the experts during the consensus meetings.
We recently informed the applicants about the evaluation results for their proposals.
For questions, please contact [email protected]
Call HORIZON-JU-GH-EDCTP3-2024-01-two-stage closed on April 4th, 2024.
240 proposals have been submitted.
The breakdown per topic is:
- HORIZON-JU-GH-EDCTP3-2024-01-01-two-stage: 21
- HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage: 22
- HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage: 28
- HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage: 32
- HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage: 54
- HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage: 83
Evaluation results are expected to be communicated in July 2024.